OBJECTIVE: Rapid reversal of the anticoagulatory effect of vitamin K antagonists represents the primary emergency treatment for oral anticoagulant-related intracerebral hemorrhage (OAC-ICH). Predicting the amount of prothrombin complex concentrate (PCC) needed to reverse OAC in individual patients is difficult, and repeated international normalized ratio (INR) measurements in central laboratories (CLs) are time-consuming. Accuracy and effectiveness of point-of-care INR coagulometers (POCs) for INR reversal in OAC-ICH have not been evaluated. METHODS: In phase 1, the agreement of emergency POC and CL INR measurements was determined. In phase 2, stepwise OAC reversal was performed with PCC using a predetermined dosing schedule. Concordance of POC and CL INR measurements during reversal and time gain due to POC were determined. RESULTS: In phase 1 (n = 165), Bland-Altman analysis showed close agreement between POCs and CLs (mean INR deviation 0.04). In phase 2 (n = 26), POCs caused a median initial net time gain of 24 minutes for the start of treatment with PCC. Median time for POC-documented complete OAC reversal was 28 minutes, compared with 120 minutes for CLs. Bland-Altman analysis between POCs and CLs revealed a mean INR deviation of 0.13 during stepwise PCC administration. POCs tended to slightly overestimate the INR, especially at higher INR levels. Remarkably, POC-guided reversal led to a median reduction of 30.5% of PCC dose compared with the a priori dose calculation. Hematomas enlarged in 20% of patients. INTERPRETATION: POC INR monitoring is a fast, effective, and economic means of PCC dose-titration in OAC-ICH. Larger studies examining the clinical efficacy of this procedure are warranted.
OBJECTIVE: Rapid reversal of the anticoagulatory effect of vitamin K antagonists represents the primary emergency treatment for oral anticoagulant-related intracerebral hemorrhage (OAC-ICH). Predicting the amount of prothrombin complex concentrate (PCC) needed to reverse OAC in individual patients is difficult, and repeated international normalized ratio (INR) measurements in central laboratories (CLs) are time-consuming. Accuracy and effectiveness of point-of-care INR coagulometers (POCs) for INR reversal in OAC-ICH have not been evaluated. METHODS: In phase 1, the agreement of emergency POC and CL INR measurements was determined. In phase 2, stepwise OAC reversal was performed with PCC using a predetermined dosing schedule. Concordance of POC and CL INR measurements during reversal and time gain due to POC were determined. RESULTS: In phase 1 (n = 165), Bland-Altman analysis showed close agreement between POCs and CLs (mean INR deviation 0.04). In phase 2 (n = 26), POCs caused a median initial net time gain of 24 minutes for the start of treatment with PCC. Median time for POC-documented complete OAC reversal was 28 minutes, compared with 120 minutes for CLs. Bland-Altman analysis between POCs and CLs revealed a mean INR deviation of 0.13 during stepwise PCC administration. POCs tended to slightly overestimate the INR, especially at higher INR levels. Remarkably, POC-guided reversal led to a median reduction of 30.5% of PCC dose compared with the a priori dose calculation. Hematomas enlarged in 20% of patients. INTERPRETATION: POC INR monitoring is a fast, effective, and economic means of PCC dose-titration in OAC-ICH. Larger studies examining the clinical efficacy of this procedure are warranted.
Authors: Timolaos Rizos; Ekkehart Jenetzky; Christian Herweh; Andreas Unterberg; Werner Hacke; Roland Veltkamp Journal: Neurocrit Care Date: 2010-12 Impact factor: 3.210
Authors: Jan C Purrucker; Timolaos Rizos; Kirsten Haas; Marcel Wolf; Shujah Khan; Peter U Heuschmann; Roland Veltkamp Journal: Neurocrit Care Date: 2017-10 Impact factor: 3.210
Authors: David J Seiffge; Christopher Traenka; Alexandros Polymeris; Lisa Hert; Urs Fisch; Nils Peters; Gian Marco De Marchis; Raphael Guzman; Christian H Nickel; Philipp A Lyrer; Leo H Bonati; Dimitrios Tsakiris; Stefan Engelter Journal: J Thromb Thrombolysis Date: 2017-01 Impact factor: 2.300
Authors: S Horstmann; T Rizos; M Lauseker; M Möhlenbruch; E Jenetzky; W Hacke; Th Steiner; R Veltkamp Journal: J Neurol Date: 2013-05-05 Impact factor: 4.849
Authors: Christopher Beynon; Angelina G Erk; Anna Potzy; Stefan Mohr; Erik Popp Journal: Scand J Trauma Resusc Emerg Med Date: 2015-08-12 Impact factor: 2.953